Search clinical trials for: naltrexone plus bupropion

Total 5562 results

Takeda

Withdrawn

Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery

Weight Regain Post Bariatric Surgery

United States
Walter Ling
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder (ADAPT)

Methamphetamine Use Disorder

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Breast Cancer Research Foundation; American Institute for Cancer Research; Hopkins-WellSpan...

Active, not recruiting

Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study (A-NEW)

Breast Cancer | Overweight or Obesity

United States
University of California, San Francisco

Completed

A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone

Multiple Sclerosis

United States
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder

Binge-Eating Disorder

United States
St. Joseph's Healthcare Hamilton
Bausch Health, Canada Inc.

Active, not recruiting

Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program. (COR-WM)

Obesity

Canada
University of California, Los Angeles

Withdrawn

Relapse Prevention in Stimulant Use Disorder

ADHD | Cognitive Function | Relapse | Stimulant Use

United States
St. Joseph's Healthcare Hamilton
Bausch Health, Canada Inc.

Active, not recruiting

A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgery (COR-WR)

Obesity

Canada
Orexigen Therapeutics, Inc

Completed

Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers

Healthy

United States
Orexigen Therapeutics, Inc

Completed

A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects

Obesity | Overweight

United States
University of Texas Southwestern Medical Center
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Completed

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder (ADAPT-2)

Methamphetamine Use Disorder

United States
Johns Hopkins University
National Institute on Drug Abuse (NIDA)

Completed

Employment-Based Depot Naltrexone Clinical Trial II

Opiate Dependence

United States
Xhale Assurance
National Institute on Drug Abuse (NIDA)

Completed

An Adherence Tool to Manage Narcotic -Addicted HIV Patients

Healthy Adults

United States
Oslo University Hospital
Orexigen Therapeutics, Inc

Withdrawn

Naltrexone/Bupropion (Mysimba) to Optimize Weight Outcomes After Obesity Surgery

Obesity
Gangnam Severance Hospital

Completed

Effects of Mediterranean Diet and Naltrexone/Bupropion Treatment in Obese Breast Cancer Patients

Obesity | Breast Cancer | Overweight

Korea, Republic of
Orexigen Therapeutics, Inc

Completed

Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity

Obesity

United States
San Diego State University

Recruiting

Understanding How Opioids Affect the Experiential and Neural Signatures of Social Experiences

Placebo | Naltrexone

United States
University of Minnesota
National Institute on Drug Abuse (NIDA)

Unknown

Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation

Tobacco Use Disorder

United States
Shanghai Mental Health Center
University of Massachusetts, Worcester

Completed

Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia

Schizophrenia | Obese | Cigarette-smoking
Orexigen Therapeutics, Inc

Terminated

Naltrexone/Bupropion Cardiovascular Outcomes Study

Cardiovascular Diseases | Obesity

United States
Orexigen Therapeutics, Inc

Completed

Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy Participants

Healthy Subjects
Brown University
National Institute on Drug Abuse (NIDA)

Completed

Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia

Tobacco Use Disorder | Schizophrenia and Disorders With Psychotic Features

United States
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Pharmacological and Behavioral Treatment After Bariatric Surgery

Obesity

United States
Zuyderland Medisch Centrum
Nederlandse Obesitas Kliniek

Recruiting

Use of Mysimba in Patients With Weight Regain After Bariatric Surgery

Obesity, Morbid | Bariatric Surgery Candidate | Medication Persistence

Netherlands
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Terminated

Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders

Obesity | Binge-Eating Disorder

United States
Yale University

Completed

Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo

Binge Eating Disorder

United States
NYU Langone Health
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users

Alcohol Dependence | Alcohol Use Disorder

United States
Columbia University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Weight Loss Study: Genetics and Response to Naltrexone/Bupropion

Obesity

United States
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy

Obesity | Binge-Eating Disorder

United States
Currax Pharmaceuticals

Recruiting

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) (INFORMUS)

Obesity

United States
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)

Loss-of-control Eating | Obesity/Overweight

United States
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Enrolling by invitation

Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a)

Obesity/Overweight | Loss-of-Control Eating

United States
National Institute on Drug Abuse (NIDA)

Completed

Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study

Methamphetamine Dependence

United States
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Alcohol Pharmacotherapy for HIV+ Prisoners (INSPIRE)

Alcohol Dependence | Human Immunodeficiency Virus | AIDS | Hazardous Drinking | Problem Drinking

United States
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Active, not recruiting

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment

Obesity | Binge-eating Disorder

United States
Orexigen Therapeutics, Inc

Completed

A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression

Depression

United States
Orexigen Therapeutics, Inc

Terminated

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

Obesity | Overweight

United States
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment

Obesity | Binge-Eating Disorder

United States
Alkermes, Inc.

Terminated

ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997])

Alcoholism | Opiate Dependence
Pfizer

Completed

Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain

Pain

United States
Orexigen Therapeutics, Inc

Completed

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects

Obesity | Overweight

United States
Orexigen Therapeutics, Inc

Completed

A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent

Obesity | Overweight | Nicotine Dependence

United States
Alkermes, Inc.

Completed

ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults

Alcoholism
Orexigen Therapeutics, Inc

Completed

A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes

Obesity | Diabetes Mellitus, Type 2 | Overweight

United States
University of Nebraska

Completed

Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic

Obesity

United States
Orexigen Therapeutics, Inc

Completed

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

Heart Repolarization

United States
Pfizer

Completed

A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

Osteoarthritis | Chronic Pain

United States
Alkermes, Inc.

Completed

ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids

Opiate Dependence
National and Kapodistrian University of Athens
Athens Medical Center

Recruiting

Study of the Cardiometabolic Effects of Obesity Pharmacotherapy

Obesity | Blood Pressure

Greece
Orexigen Therapeutics, Inc

Completed

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program

Obesity | Overweight

United States

Search clinical trials for: naltrexone plus bupropion

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations